CY1122809T1 - Εστερικα προ-φαρμακα της [3-(1-(1η-ιμιδαζολ-4-υλ)αιθυλο)-2-μεθυλοφαινυλο) μεθανολης για τη θεραπεια οφθαλμικων νοσηματων - Google Patents

Εστερικα προ-φαρμακα της [3-(1-(1η-ιμιδαζολ-4-υλ)αιθυλο)-2-μεθυλοφαινυλο) μεθανολης για τη θεραπεια οφθαλμικων νοσηματων

Info

Publication number
CY1122809T1
CY1122809T1 CY20201100365T CY201100365T CY1122809T1 CY 1122809 T1 CY1122809 T1 CY 1122809T1 CY 20201100365 T CY20201100365 T CY 20201100365T CY 201100365 T CY201100365 T CY 201100365T CY 1122809 T1 CY1122809 T1 CY 1122809T1
Authority
CY
Cyprus
Prior art keywords
treatment
methylphenyl
ethyl
eye diseases
imidazol
Prior art date
Application number
CY20201100365T
Other languages
English (en)
Inventor
Mohammed I. Dibas
Daniel W. Gil
Ken Chow
Liming Wang
Michael E. Garst
John E. Donello
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44675870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122809(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of CY1122809T1 publication Critical patent/CY1122809T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με μια μέθοδο για τη θεραπεία οφθαλμικών νοσημάτων σε ένα υποκείμενο το οποίο χρήζει μια τέτοιας θεραπείας, που περιλαμβάνει τη χορήγηση μιας θεραπευτικά αποτελεσματικής ποσότητας μιας σύνθεσης η οποία περιλαμβάνει προ-φάρμακα εστέρα της [3-(1-(1Η-ιμιδαζολ-4-υλ)αιθυλο)-2-μεθυλοφαινυλο) μεθανόλης, τις διαδικασίες παρασκευής τους, τις φαρμακευτικές συνθέσεις οι οποίες τα περιέχουν και τη χρήση τους ως φάρμακα.
CY20201100365T 2010-09-16 2020-04-21 Εστερικα προ-φαρμακα της [3-(1-(1η-ιμιδαζολ-4-υλ)αιθυλο)-2-μεθυλοφαινυλο) μεθανολης για τη θεραπεια οφθαλμικων νοσηματων CY1122809T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38337010P 2010-09-16 2010-09-16
EP11760958.6A EP2616066B1 (en) 2010-09-16 2011-09-16 Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]methanol for treating retinal diseases
EP16161921.8A EP3078376B1 (en) 2010-09-16 2011-09-16 Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
PCT/US2011/051926 WO2012037453A1 (en) 2010-09-16 2011-09-16 Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases

Publications (1)

Publication Number Publication Date
CY1122809T1 true CY1122809T1 (el) 2021-05-05

Family

ID=44675870

Family Applications (3)

Application Number Title Priority Date Filing Date
CY181100852T CY1121024T1 (el) 2010-09-16 2018-08-13 Προ-φαρμακα εστερα της [3-(1-(1η-ιμιδαζολ-4-υλ)αιθυλ)-2-μεθυλφαινυλ] μεθανολης για μειωση ενδοοφθαλμικης πιεσης
CY20201100265T CY1122958T1 (el) 2010-09-16 2020-03-20 Προ-φαρμακα εστερα της [3-(1-(1η-ιμιδαζολ-4-υλ)αιθυλ)-2-μεθυλφαινυλ] μεθανολης για μειωση ενδοοφθαλμικης πιεσης
CY20201100365T CY1122809T1 (el) 2010-09-16 2020-04-21 Εστερικα προ-φαρμακα της [3-(1-(1η-ιμιδαζολ-4-υλ)αιθυλο)-2-μεθυλοφαινυλο) μεθανολης για τη θεραπεια οφθαλμικων νοσηματων

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY181100852T CY1121024T1 (el) 2010-09-16 2018-08-13 Προ-φαρμακα εστερα της [3-(1-(1η-ιμιδαζολ-4-υλ)αιθυλ)-2-μεθυλφαινυλ] μεθανολης για μειωση ενδοοφθαλμικης πιεσης
CY20201100265T CY1122958T1 (el) 2010-09-16 2020-03-20 Προ-φαρμακα εστερα της [3-(1-(1η-ιμιδαζολ-4-υλ)αιθυλ)-2-μεθυλφαινυλ] μεθανολης για μειωση ενδοοφθαλμικης πιεσης

Country Status (29)

Country Link
US (9) US8501796B2 (el)
EP (13) EP2616066B1 (el)
JP (4) JP2013541527A (el)
KR (7) KR101840501B1 (el)
CN (5) CN103200942A (el)
AR (4) AR083017A1 (el)
AU (4) AU2011301901B2 (el)
BR (4) BR112013006320B1 (el)
CA (8) CA3079450A1 (el)
CL (4) CL2013000736A1 (el)
CY (3) CY1121024T1 (el)
DK (9) DK3338777T3 (el)
ES (10) ES2687420T3 (el)
HK (5) HK1185538A1 (el)
HU (5) HUE047476T2 (el)
IL (4) IL225280A0 (el)
MX (4) MX2013003008A (el)
MY (4) MY173846A (el)
NZ (1) NZ608751A (el)
PL (7) PL3050563T3 (el)
PT (7) PT3050564T (el)
RU (4) RU2612351C2 (el)
SG (4) SG188570A1 (el)
SI (5) SI3050563T1 (el)
TR (1) TR201909249T4 (el)
TW (4) TW201240661A (el)
UA (1) UA112973C2 (el)
WO (4) WO2012037490A1 (el)
ZA (4) ZA201302194B (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010213580A1 (en) * 2009-02-13 2011-09-08 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
US9248123B2 (en) 2010-01-11 2016-02-02 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
US8501796B2 (en) * 2010-09-16 2013-08-06 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure
RU2014105894A (ru) * 2011-07-22 2015-08-27 Аллерган, Инк. Альфа-2-адренергические модуляторы для лечения расстройств зрения, опосредованных центральными зрительными проекциями из глаз
AU2012340806B2 (en) 2011-11-21 2017-10-19 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases
USD794650S1 (en) 2014-11-28 2017-08-15 Samsung Electronics Co., Ltd. Display screen or portion thereof with a graphical user interface
CN108310442B (zh) * 2017-01-17 2021-08-27 台北科技大学 眼科用组合物
KR102050506B1 (ko) 2017-06-20 2019-11-29 한국식품연구원 망막 질환 예방, 개선, 완화 또는 치료용 조성물
CN108872431B (zh) * 2018-07-09 2021-03-23 成都倍特药业股份有限公司 一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法
CN112552314B (zh) * 2018-08-24 2022-03-04 杭州阿诺生物医药科技有限公司 Sting激动剂小分子抗肿瘤化合物及其应用
EP4322943A1 (en) * 2021-04-16 2024-02-21 ADS Therapeutics LLC Alpha2 adrenergic agonist codrugs conjugated with muscarinic agonist drugs

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0642332T3 (da) 1992-05-13 1997-06-16 Sandoz Ltd Ophthalmiske præparater indeholdende cyclosporin
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
NZ330898A (en) 1993-11-15 2000-01-28 Schering Corp Phenyl-alkyl imidazoles as H3-receptor antagonists in particular for the treatment of inflammation
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
DE602004015600D1 (de) * 2003-05-27 2008-09-18 Sod Conseils Rech Applic Neue imidazolderivative, deren herstellung und deren verwendung als medikament
US20060209374A1 (en) * 2003-07-14 2006-09-21 Koninklijke Philips Electronics N.V. Projection device
AU2004279336A1 (en) * 2003-09-12 2005-04-21 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
EP2481412B1 (en) * 2004-05-25 2017-09-27 Galderma Pharma S.A. Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US20050277584A1 (en) 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
MX2007003068A (es) 2004-09-24 2007-05-21 Allergan Inc 4-(fenil-metil y fenil-metil substituido)-imidazol-2tionas como agonistas adrenergicos alfa2 especificos.
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US20070082070A1 (en) * 2005-10-11 2007-04-12 Stookey Evangeline L Treating skin disorders
US7902247B2 (en) 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
EP2393800B1 (en) 2009-02-06 2014-10-08 Allergan, Inc. Pyridine compounds as subtype selective modulators of alpha2b and/or alpha 2c adrenergic receptors
AU2010213580A1 (en) 2009-02-13 2011-09-08 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US8501796B2 (en) 2010-09-16 2013-08-06 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure

Also Published As

Publication number Publication date
CY1121024T1 (el) 2019-12-11
AU2011301847A1 (en) 2013-05-02
HUE038698T2 (hu) 2018-11-28
IL225281A0 (en) 2013-06-27
IL225280A0 (en) 2013-06-27
ES2788051T3 (es) 2020-10-20
AU2011301856C1 (en) 2016-09-08
RU2013116405A (ru) 2014-10-27
ES2737230T3 (es) 2020-01-10
KR102354097B1 (ko) 2022-01-20
EP2616069B1 (en) 2016-11-16
US20160354346A1 (en) 2016-12-08
TW201240661A (en) 2012-10-16
EP3078376A1 (en) 2016-10-12
CN103209694A (zh) 2013-07-17
DK3348264T3 (da) 2020-03-23
CN105412092A (zh) 2016-03-23
CN103200941A (zh) 2013-07-10
DK3050563T3 (en) 2018-08-13
ZA201302291B (en) 2013-11-27
EP2616067A1 (en) 2013-07-24
KR101840501B1 (ko) 2018-05-04
MX2013003008A (es) 2013-06-28
ES2760920T3 (es) 2020-05-18
CA2812195A1 (en) 2012-03-22
DK3053576T3 (en) 2018-08-20
KR101952457B1 (ko) 2019-02-26
EP3348264B1 (en) 2020-01-01
KR20140005154A (ko) 2014-01-14
CA3122745A1 (en) 2012-03-22
EP2616066A1 (en) 2013-07-24
BR112013006320A2 (pt) 2016-06-21
CN105412092B (zh) 2020-11-17
JP6073229B2 (ja) 2017-02-01
EP3698789A1 (en) 2020-08-26
DK3636263T3 (da) 2022-01-10
AU2011301932C1 (en) 2016-09-01
KR20200044147A (ko) 2020-04-28
EP3659600A1 (en) 2020-06-03
EP3050563B1 (en) 2018-05-09
NZ608751A (en) 2015-04-24
ES2613509T3 (es) 2017-05-24
HK1185538A1 (zh) 2014-02-21
ES2684055T3 (es) 2018-10-01
KR20140003407A (ko) 2014-01-09
EP3053576A1 (en) 2016-08-10
EP2616068A1 (en) 2013-07-24
BR112013006320B1 (pt) 2022-08-30
KR101840500B1 (ko) 2018-03-20
UA112973C2 (uk) 2016-11-25
ES2593612T3 (es) 2016-12-12
KR20190022895A (ko) 2019-03-06
IL225282A0 (en) 2013-06-27
SI3348264T1 (sl) 2020-07-31
EP3053576B1 (en) 2018-05-16
ZA201302194B (en) 2013-11-27
ZA201302193B (en) 2013-11-27
SG188573A1 (en) 2013-04-30
PL3348264T3 (pl) 2020-08-24
PT3338777T (pt) 2020-05-06
EP3050564B1 (en) 2019-09-04
JP2013540749A (ja) 2013-11-07
MX2013003002A (es) 2013-06-28
CN103200941B (zh) 2015-12-16
KR20130114140A (ko) 2013-10-16
CA2811559A1 (en) 2012-03-22
PL3338777T3 (pl) 2020-07-13
CL2013000733A1 (es) 2013-08-23
HUE049573T2 (hu) 2020-10-28
AU2011301856A1 (en) 2013-05-02
RU2013116541A (ru) 2014-10-27
TW201305116A (zh) 2013-02-01
HUE048725T2 (hu) 2020-09-28
WO2012037484A1 (en) 2012-03-22
SG188571A1 (en) 2013-04-30
EP3348264A1 (en) 2018-07-18
CA2812197A1 (en) 2012-03-22
AR083019A1 (es) 2013-01-23
HK1185541A1 (zh) 2014-02-21
US8853251B2 (en) 2014-10-07
PL3050563T3 (pl) 2018-12-31
CA2812191C (en) 2021-04-13
TWI591058B (zh) 2017-07-11
US20120122945A1 (en) 2012-05-17
AU2011301901B2 (en) 2016-02-11
SI3050564T1 (sl) 2020-02-28
US20120136036A1 (en) 2012-05-31
JP6045495B2 (ja) 2016-12-14
CL2013000734A1 (es) 2013-11-08
CA3077732A1 (en) 2012-03-22
AU2011301932A1 (en) 2013-05-02
EP3338777B1 (en) 2020-02-05
RU2612351C2 (ru) 2017-03-07
SG188570A1 (en) 2013-04-30
US20140057958A1 (en) 2014-02-27
ES2687420T3 (es) 2018-10-25
HK1257416A1 (zh) 2019-10-18
HK1185540A1 (zh) 2014-02-21
TR201909249T4 (tr) 2019-07-22
PT3050563T (pt) 2018-10-01
IL225278A0 (en) 2013-06-27
TW201240662A (en) 2012-10-16
ZA201302288B (en) 2013-11-27
CA2812191A1 (en) 2012-03-22
CA2812197C (en) 2024-01-02
US20130289088A1 (en) 2013-10-31
TW201305117A (zh) 2013-02-01
HUE047476T2 (hu) 2020-04-28
ES2607084T3 (es) 2017-03-29
RU2013116403A (ru) 2014-10-27
PT3050564T (pt) 2019-12-11
EP2616066B1 (en) 2016-07-13
MX2013003004A (es) 2013-06-28
HK1185539A1 (zh) 2014-02-21
CL2013000736A1 (es) 2013-07-12
EP3050564A1 (en) 2016-08-03
CN103221045A (zh) 2013-07-24
EP2616069A1 (en) 2013-07-24
EP3636263A1 (en) 2020-04-15
CA3116249A1 (en) 2012-03-22
DK3050564T3 (da) 2019-11-25
AR083020A1 (es) 2013-01-23
MY168763A (en) 2018-12-04
CN103200942A (zh) 2013-07-10
CA3079450A1 (en) 2012-03-22
US20130296394A1 (en) 2013-11-07
AR083017A1 (es) 2013-01-23
BR112013006362A2 (pt) 2016-06-28
WO2012037490A1 (en) 2012-03-22
PT2616069T (pt) 2016-12-06
ES2781681T3 (es) 2020-09-04
CL2013000735A1 (es) 2013-11-29
US20120142746A1 (en) 2012-06-07
EP3338777A1 (en) 2018-06-27
EP3636263B1 (en) 2021-11-03
MY191369A (en) 2022-06-20
EP3078376B1 (en) 2019-03-27
SI3053576T1 (sl) 2018-11-30
US8492422B2 (en) 2013-07-23
EP3050563A1 (en) 2016-08-03
JP2013537236A (ja) 2013-09-30
HUE039090T2 (hu) 2018-12-28
PT3348264T (pt) 2020-04-02
PT3053576T (pt) 2018-10-08
BR112013006352A2 (pt) 2016-06-28
AU2011301847B2 (en) 2016-02-11
MY161607A (en) 2017-04-28
AR083018A1 (es) 2013-01-23
US8653123B2 (en) 2014-02-18
WO2012037499A1 (en) 2012-03-22
US8492557B2 (en) 2013-07-23
US20120149746A1 (en) 2012-06-14
JP2013537237A (ja) 2013-09-30
EP2616067B1 (en) 2016-05-18
KR102139905B1 (ko) 2020-07-31
JP2013541527A (ja) 2013-11-14
MY173846A (en) 2020-02-24
DK3338777T3 (da) 2020-04-20
DK2616068T3 (en) 2016-08-29
SI3050563T1 (sl) 2018-10-30
PT2616068T (pt) 2016-09-13
ES2904479T3 (es) 2022-04-05
BR112013006355A2 (pt) 2016-06-28
CY1122958T1 (el) 2021-10-29
US8501796B2 (en) 2013-08-06
PL2616068T3 (pl) 2016-11-30
WO2012037453A1 (en) 2012-03-22
US20150148394A1 (en) 2015-05-28
KR102104760B1 (ko) 2020-04-27
MX2013003009A (es) 2013-06-28
PL3050564T3 (pl) 2020-06-01
DK3078376T3 (da) 2019-06-24
AU2011301901A1 (en) 2013-05-02
KR20200091507A (ko) 2020-07-30
SG188572A1 (en) 2013-04-30
PL2616069T3 (pl) 2017-04-28
PL3053576T3 (pl) 2018-11-30
EP2616068B1 (en) 2016-07-13
AU2011301932B2 (en) 2016-02-25
KR20130105658A (ko) 2013-09-25
RU2013116763A (ru) 2014-10-27
SI3338777T1 (sl) 2020-08-31
IL225278A (en) 2015-11-30
DK2616069T3 (en) 2016-12-19

Similar Documents

Publication Publication Date Title
CY1122809T1 (el) Εστερικα προ-φαρμακα της [3-(1-(1η-ιμιδαζολ-4-υλ)αιθυλο)-2-μεθυλοφαινυλο) μεθανολης για τη θεραπεια οφθαλμικων νοσηματων
CY1122629T1 (el) Αιθυλεστερας εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιας
CY1123945T1 (el) Στοματικα σκευασματα αμεσης απελευθερωσης για υποκατεστημενες κιναζολινονες
CY1123549T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
CY1123749T1 (el) Μεθοδοι μειωσης του κινδυνου καρδιαγγειακου γεγονοτος σε ενα υποκειμενο επι θεραπειας στατινης χρησιμοποιωντας αιθυλ εστερα εικοσαπενταενοϊκου οξεος
CY1122713T1 (el) Στοματικα χορηγουμενες συνθεσεις κορτικοστεροειδων
CY1119684T1 (el) Αντι-ιικες ενωσεις
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1121776T1 (el) C17-αλκανοδιυλιο και παραγωγα αλκενοδιυλιου του ολεανολικου οξεος και μεθοδοι χρησης αυτων
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
CY1119387T1 (el) Τριαζολοπυραζινες ως αναστολεις brd4 για χρηση στην αντιμετωπιση καρκινου
CY1116987T1 (el) Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις
CY1116057T1 (el) Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3
UA111770C2 (uk) Інгібітори бромдомену
CY1115043T1 (el) Φαρμακευτικο σκευασμα
WO2012173682A3 (en) Compounds and methods for the treatment of isocitrate dehydrognase related diseases
EA201491726A1 (ru) Конъюгаты бороновых кислот олигонуклеотидных аналогов
CY1118947T1 (el) Ασυμμετρες ουριες και ιατρικες χρησεις αυτων
CY1116775T1 (el) Παραγωγα πυριμιδονης ως αναστολεις της ιστικης τρανσγλουταμινασης
CY1115556T1 (el) Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη
CY1113240T1 (el) Αλατα ενωσεων αναστολεα hiv
CY1124505T1 (el) Κρυσταλλικες μορφες βιλαστινης και μεθοδοι παρασκευης αυτων
IN2014CN03214A (el)
CY1117723T1 (el) Παραγωγα στερολης, μεθοδος για την παρασκευη των ιδιων, φαρμακευτικες συνθεσεις οι οποιες περιεχουν τα ιδια και χρηση αυτων για την αγωγη πολλαπλων γλοιοβλαστωματων
CY1121280T1 (el) Χρηση της θυαζολοπυριμιδινονης για τη θεραπεια της φλεγμονωδους νοσου του εντερου